Presentation is loading. Please wait.

Presentation is loading. Please wait.

Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m.

Similar presentations


Presentation on theme: "Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m."— Presentation transcript:

1 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4 5-FU 1000mg/m 2 d1-4 Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4 5-FU 1000mg/m 2 d1-4 Radiochemotherapy 70 Gy + Cisplatin 100 mg /m 2 d1, 22, Gy + Cisplatin 100 mg /m 2 d1, 22, 43Radiochemotherapy Laryngoprotect-Study R. Knecht et al. Laryngoprotect-Study

2 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Regions and stages in % 55% 24% 21% T/N N1N1N1N1 N2N2N2N2 N3N3N3N T2T2T2T2 T3T3T3T3 T4T4T4T N0N0N0N0 Stage II Stage III Stage IV 7 66 n=103

3 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Toxicity (WHO Grad III / IV) Renal 25% Afebrile Neutropenia 95% Nausea/Vomiting 25% Mucositis 10% Sensory Neuropathy 10% 4% 47% 20% 43% 5% Inductionchemotherapy Radio-chemotherapy

4 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Results after TPF - Polychemotherapy (3 Cycles) Results SupraglottisGlottisHypopharynxSupraglottisGlottisHypopharynx RRRR 76%73%92%79%76%73%92%79%41%53%54%47%41%53%54%47% CRCR

5 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht postResults after TPF - Polychemotherapy (3 Cycles) Results prae S. A., T3N3M0

6 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht post prae B. W., T2N1M0Results after TPF - Polychemotherapy (3 Cycles) Results

7 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht prae B. W., T2N1M0 postResults after TPF - Polychemotherapy(3 Cycles) Results

8 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht postprae M. B., T2N1M0 Results after TPF - Polychemotherapy (3 Cycles) Results

9 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht post prae B. H., T2N2bM0 Results after TPF - Polychemotherapy (3 Cycles) Results

10 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht post prae G. H., T2N2bM0 Results after TPF - Polychemotherapy (3 Cycles) Results

11 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht post prae J. H., T2N2bM0 Results after TPF - Polychemotherapy (3 Cycles) Results

12 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) Induction chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) Laryngoprotect n = 103 Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 ) 74%75%2%93%74%75%2%93% Larynx preservation Disease free surv. Distant metastasis Survival Larynx preservation Disease free surv. Distant metastasis Survival 2 yearsResultsHypopharynxResultsHypopharynx Knecht R. et al. (2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559

13 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induktion chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) Induktion chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) 2 years Laryngoprotect n = %85%0%94%91%85%0%94% Larynx preservation Disease free surv. Distant metastasis Survival Larynx preservation Disease free surv. Distant metastasis Survival Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )ResultsLarynxResultsLarynx Knecht R. et al. (2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559

14 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) Induction chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) 2 years Laryngoprotect n = %85%0%94%91%85%0%94% Larynx preservation Disease free surv. Distant metastasis Survival Larynx preservation Disease free surv. Distant metastasis Survival Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )ResultsLarynxResultsLarynxRadiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 ) RTOG n = %61%8%74%88%61%8%74% Knecht R. et al. (2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559

15 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Laryngoprotect 2 Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 ) Induction chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) Induction chemotherapy 3 Cycles Cisplatin (100mg/m 2 ) 5 Fluorouracil (4000mg/m 2 ) Docetaxel (75mg/m 2 ) Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 )Radiochemotherapy (70Gy) Cisplatin (3x 100mg/m 2 ) 2

16 Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4 Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4 Radiochemotherapy 70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m 2 total) Radiochemotherapy Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4 Cetuximab (400 mg d1; 250mg ab d8 wöchtl) Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4 Cetuximab (400 mg d1; 250mg ab d8 wöchtl) International principal investigator: R. Knecht Stage III/IV EGFR-Antibody Neoadjuvant Primary Therapy EGFR-Antibody


Download ppt "Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m."

Similar presentations


Ads by Google